STAT Plus: Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available
Hello, everyone, and nice to see you again after a brief sojourn in a foreign…
Category: Biotech
OxyContin maker thrives in China with abandoned U.S. tactics
SHANGHAI — OxyContin is a dying business in the United States. Purdue Pharma, owned by…
Opinion: Some bipartisan support for biosimilars is good. More would be better
In today’s hyperpartisan and gridlocked political climate, we should seize any opportunity for bipartisan agreement…
Opinion: Letting academic medical centers make CAR-T drugs would save billions
Draw blood from someone with cancer. Engineer their blood cells to seek and destroy cancer….
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…
Trump’s stalling on flavored vape ban draws blowback — and fears of lasting damage to American health
The Trump administration’s apparent decision to back off a plan to ban flavored e-cigarettes has…
STAT Plus: Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?
Good morning. Elizabeth Cooney here again in Boston while Ed Silverman completes another engagement abroad….
First CRISPR treatment for blood diseases shows early benefits in two patients
The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle…
STAT Plus: Novo Nordisk’s parent company to launch research incubator in Boston
Novo Holdings, the investment firm behind pharmaceutical giant Novo Nordisk, is committing $25 million over…
How Purdue planted its ‘anti-story’ and delayed the reckoning for its role in the opioid epidemic
This story is a collaboration between STAT and ProPublica. In 2004, Purdue Pharma was facing…
Opinion: In the hospital supply chain, too many choices can be costly
Not long ago, I did a small experiment at a hospital in Texas: I put…